دورية أكاديمية
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
| العنوان: | Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial |
|---|---|
| المؤلفون: | Thiery-Vuillemin, Antoine, de Bono, Johann, Hussain, Maha, Roubaud, Guilhem, Procopio, Giuseppe, Shore, Neal, Fizazi, Karim, dos Anjos, Gabriel, Gravis, Gwenaelle, Joung, Jae Young, Matsubara, Nobuaki, Castellano, Daniel, Degboe, Arnold, Gresty, Chris, Kang, Jinyu, Allen, Allison, Poehlein, Christian, Saad, Fred |
| المساهمون: | Merck, Merck Sharp and Dohme, AstraZeneca |
| المصدر: | The Lancet Oncology ; volume 23, issue 3, page 393-405 ; ISSN 1470-2045 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Oncology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/s1470-2045(22)00017-1 |
| الإتاحة: | https://doi.org/10.1016/s1470-2045Test(22)00017-1 https://api.elsevier.com/content/article/PII:S1470204522000171?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S1470204522000171?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://www.elsevier.com/open-access/userlicense/1.0Test/ ; https://doi.org/10.15223/policy-017Test ; https://doi.org/10.15223/policy-037Test ; https://doi.org/10.15223/policy-012Test ; https://doi.org/10.15223/policy-029Test ; https://doi.org/10.15223/policy-004Test |
| رقم الانضمام: | edsbas.A3CFBF12 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/s1470-2045(22)00017-1 |
|---|